The founder of Ionis is betting on personalized medicine in the most literal sense
Antisense pioneer Stanley Crooke has a new job: The former Ionis Pharmaceuticals CEO will be heading up the nonprofit n-Lorem Foundation, which aims to create N-of-1 drugs — hyper-individualized antisense oligonucleotide therapies for patients with ultra-rare diseases.
Such treatments entered the spotlight back in 2018, when Boston Children's researchers revealed they'd created a bespoke therapy for a young girl named Mila Makovec with the rare, inherited Batten's disease. News of the drug, milasen, led to an influx of patient interest — with parents of other children with such rare disorders clamoring for their own individualized treatment.
Crooke has contributed $1.5 million of his own money to the nonprofit, Chemical & Engineering News writes. Biogen has donated $1 million, and several individuals have also given money to the effort.
Such treatments entered the spotlight back in 2018, when Boston Children's researchers revealed they'd created a bespoke therapy for a young girl named Mila Makovec with the rare, inherited Batten's disease. News of the drug, milasen, led to an influx of patient interest — with parents of other children with such rare disorders clamoring for their own individualized treatment.
Crooke has contributed $1.5 million of his own money to the nonprofit, Chemical & Engineering News writes. Biogen has donated $1 million, and several individuals have also given money to the effort.
.png)
No hay comentarios:
Publicar un comentario